BDBM384368 US10590114, No. 54B::US11111235, No. 54B::US11591316, Compound 54B::US9932325, Example 54A::US9932325, Example 54B

SMILES CCNc1nc(Nc2cnn3CC(Cc23)n2nccn2)ncc1C(F)(F)F

InChI Key InChIKey=JZUKWWQGMGJGRD-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 384368   

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384368(US9932325, Example 54B | US9932325, Example 54A | ...)
Affinity DataIC50: 30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well assay plate DMSOEnzyme Reaction Condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384368(US9932325, Example 54B | US9932325, Example 54A | ...)
Affinity DataIC50: 30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well assay plate DMSOEnzyme Reaction Condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Denali Therapautics

US Patent
LigandPNGBDBM384368(US9932325, Example 54B | US9932325, Example 54A | ...)
Affinity DataIC50: 30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well assay plate DMSOEnzyme Reaction Condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Denali Therapautics

US Patent
LigandPNGBDBM384368(US9932325, Example 54B | US9932325, Example 54A | ...)
Affinity DataIC50: 30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well assay plate DMSOEnzyme Reaction Condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384368(US9932325, Example 54B | US9932325, Example 54A | ...)
Affinity DataIC50: 30nMAssay Description:Materials:LRRK2 G2019S enzymeSubstrate (LRRKtide)ATPTR-FRET dilution bufferpLRRKtide antibody384-well assay plateDMSOEnzyme Reaction Conditions50 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384368(US9932325, Example 54B | US9932325, Example 54A | ...)
Affinity DataIC50: 30nMAssay Description:Materials:LRRK2 G2019S enzymeSubstrate (LRRKtide)ATPTR-FRET dilution bufferpLRRKtide antibody384-well assay plateDMSOEnzyme Reaction Conditions50 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2022
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384368(US9932325, Example 54B | US9932325, Example 54A | ...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384368(US9932325, Example 54B | US9932325, Example 54A | ...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
Go to US Patent